Literature DB >> 22241717

Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients.

Valentina Piccini1, Elena Rapizzi, Alessandra Bacca, Giuseppe Di Trapani, Raffaele Pulli, Valentino Giachè, Benedetta Zampetti, Emanuela Lucci-Cordisco, Letizia Canu, Elisa Corsini, Antongiulio Faggiano, Luca Deiana, Davide Carrara, Valeria Tantardini, Stefano Mariotti, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Gabriele Parenti, Annamaria Colao, Carlo Pratesi, Giampaolo Bernini, Tonino Ercolino, Massimo Mannelli.   

Abstract

Head and neck paragangliomas (HNPGLs) are neural crest-derived tumors. In comparison with paragangliomas located in the abdomen and the chest, which are generally catecholamine secreting (sPGLs) and sympathetic in origin, HNPGLs are, in fact, parasympathetic in origin and are generally nonsecreting. Overall, 79 consecutive patients with HNPGL were examined for mutations in SDHA, SDHB, SDHC, SDHD, SDHAF2, VHL, MAX, and TMEM127 genes by PCR/sequencing. According to a detailed family history (FH) and clinical, laboratory (including metanephrines), and instrumental examinations, patients were divided into three groups: a) patients with a positive FH for HNPGL (index cases only), b) patients with a negative FH and multiple HNPGLs (synchronous or metachronous) or HNPGL associated with an sPGL, and c) patients with negative FH and single HNPGL. The ten patients in group a) proved to be SDHD mutation carriers. The 16 patients in group b) proved to be SDHD mutation carriers. Among the 53 patients in group c), ten presented with germ-line mutations (three SDHB, three SDHD, two VHL, and two SDHAF2). An sPGL was found at diagnosis or followed up in five patients (6.3%), all were SDHD mutation carriers. No SDHC, SDHA, MAX, and TMEM127 mutations were found. In SDHD mutation carriers, none of the patients affected by HNPGL associated with sPGL presented missense mutations. In conclusion, a positive FH or the presence of multiple HNPGLs is a strong predictor for germ-line mutations, which are also present in 18.8% of patients carefully classified as sporadic. The most frequently mutated gene so far is SDHD but others, including SDHB, SDHAF2, and VHL, may also be affected.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22241717     DOI: 10.1530/ERC-11-0369

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  36 in total

1.  Integrative genetic, epigenetic and pathological analysis of paraganglioma reveals complex dysregulation of NOTCH signaling.

Authors:  Alessandro Cama; Fabio Verginelli; Lavinia Vittoria Lotti; Francesco Napolitano; Annalisa Morgano; Andria D'Orazio; Michele Vacca; Silvia Perconti; Felice Pepe; Federico Romani; Francesca Vitullo; Filippo di Lella; Rosa Visone; Massimo Mannelli; Hartmut P H Neumann; Giancarlo Raiconi; Carlo Paties; Antonio Moschetta; Roberto Tagliaferri; Angelo Veronese; Mario Sanna; Renato Mariani-Costantini
Journal:  Acta Neuropathol       Date:  2013-08-18       Impact factor: 17.088

Review 2.  Structural basis for malfunction in complex II.

Authors:  Tina M Iverson; Elena Maklashina; Gary Cecchini
Journal:  J Biol Chem       Date:  2012-08-17       Impact factor: 5.157

Review 3.  Endocrine tumors associated with the vagus nerve.

Authors:  Arthur Varoquaux; Electron Kebebew; Fréderic Sebag; Katherine Wolf; Jean-François Henry; Karel Pacak; David Taïeb
Journal:  Endocr Relat Cancer       Date:  2016-07-12       Impact factor: 5.678

Review 4.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

5.  Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A 18 F-FDOPA PET/CT study.

Authors:  Vincent Amodru; Pauline Romanet; Ugo Scemama; Marion Montava; Nicolas Fakhry; Frédéric Sebag; Frédéric Castinetti; Jean-Pierre Lavieille; Anderson Loundou; Arthur Varoquaux; Anne Barlier; Karel Pacak; David Taïeb
Journal:  Head Neck       Date:  2018-12-24       Impact factor: 3.147

Review 6.  PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Authors:  Garima Gupta; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

Review 7.  Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.

Authors:  Alfred King-Yin Lam
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

8.  MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours.

Authors:  Joakim Crona; Rajani Maharjan; Alberto Delgado Verdugo; Peter Stålberg; Dan Granberg; Per Hellman; Peyman Björklund
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

Review 9.  Current and future trends in the anatomical and functional imaging of head and neck paragangliomas.

Authors:  David Taïeb; Arthur Varoquaux; Clara C Chen; Karel Pacak
Journal:  Semin Nucl Med       Date:  2013-11       Impact factor: 4.446

10.  Mutation screening in a Norwegian cohort with pheochromocytoma.

Authors:  Wenche Sjursen; Henrik Halvorsen; Eva Hofsli; Siri Bachke; Asa Berge; Lars F Engebretsen; Sture E Falkmer; Ursula G Falkmer; Jan E Varhaug
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.